Ocular Allergy

Intracanalicular insert soothes ocular itching in allergic conjunctivitis

June 16, 2017

A phase III study of dexamethasone insert, 0.4 mg (Dextenza, Ocular Therapeutix) found that the sustained-release intracanalicular insert is safe, effective, and well tolerated for treating ocular itching associated with allergic conjunctivitis.

IL-1 receptor inhibitor fails on ocular itching endpoint

August 10, 2016

Isunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.

Alcaftadine superior in reducing itching from grass, tree pollens

July 06, 2016

Alcaftadine ophthalmic solution 0.25% was superior to olopatadine hydrochloride ophthalmic solution 0.2% in reducing the itching related to grass and tree pollens in a multicenter, randomized study in subjects with allergic conjunctivitis.

New ocular allergy drug’s MOA targets inflammation

April 27, 2016

A new, first-in-class, aldehyde-trap topical drop demonstrated rapid onset of action and sustained efficacy with an acceptable safety profile in a phase II clinical trial of patients with moderate-to-severe allergic conjunctivitis.

What clinicians should know about ocular allergies

March 15, 2016

The arrival of spring also signals the onset of ocular allergy season. Clinicians can prepare by knowing and recognizing the symptoms in their patients, as well as being informed about the latest therapies for this diagnosis.

Getting to the root cause of ocular allergy

March 15, 2016

Being armed with as much information as possible about a patient’s ocular allergies can make a major difference in treatment decisions, whether for dry eye or scheduling of ocular surgery.

What punctal plug delivery of dexamethasone means for allergic conjunctivitis

March 15, 2016

Treatment of chronic allergic conjunctivitis with a sustained-release dexamethasone resulted in better clinical results because of the sustained and controlled delivery.

Allergy or dry eye: Which is it?

March 15, 2016

Ocular surface disease may be multifactorial, presenting a challenge to the physician in making a correct diagnosis and management plan.

Dual-acting, anti-allergy agent delivers efficacy, safety, convenience

February 15, 2015

Olopatadine 0.2% is a well-tolerated, safe, and effective antihistamine/mast cell stabilizer for treating mild to severe allergic conjunctivitis in children and adults.

Novel dexamethasone punctum plug for ocular allergy shows promise

February 15, 2015

A novel dexamethasone-eluting punctum plug was safe and showed some evidence of efficacy for relieving signs and symptoms of allergic conjunctivitis in a phase II study.